期刊文献+

探究同步放化疗对中晚期食管癌患者免疫功能的影响 被引量:1

Exploring the Effect of Concurrent Chemoradiotherapy on Immune Function in Patients with Advanced Esophageal Cancer
在线阅读 下载PDF
导出
摘要 目的探究同步放化疗对中晚期食管癌患者免疫功能的影响。方法选取2014年1月至2018年12月期间我院收治的60例中晚期食管癌患者,按治疗方案的区别分为实验组和对照组,每组各30例。对照组采用放射治疗联合对症支持治疗的方法,实验组则采取同步放化疗进行治疗。通过对两组患者治疗前及治疗后6个月的血清免疫球蛋白A(IgA)、免疫球蛋白M(IgM)及免疫球蛋白G(IgG)的水平变化情况进行统计分析,从而探究其免疫功能的恢复情况。结果治疗前,两组患者各项血清免疫球蛋白的水平差异无统计学意义(P>0.05);治疗后,实验组患者血清免疫球蛋白A(IgA)、免疫球蛋白M(IgM)及免疫球蛋白G(IgG)的水平均明显高于同期对照组患者的相应指标,且组间及组内差异均具有统计学意义(P<0.05)。结论同步放化疗可有效恢复中晚期食管癌患者的免疫功能,从而提高临床治疗效果,因此可尝试将该治疗方式应用于中晚期食管癌患者的治疗当中。 Objective To investigate the effect of concurrent chemoradiotherapy on immune function in patients with advanced esophageal cancer.Methods Sixty patients with advanced esophageal cancer admitted to our hospital from January 2014 to December 2018 were enrolled.The patients were divided into experimental group and control group according to the difference of treatment options,with 30 cases in each group.The control group was treated with radiotherapy combined with symptomatic supportive therapy,while the experimental group was treated with concurrent chemoradiotherapy.Through the statistical analysis of the changes of serum immunoglobulin A(IgA),immunoglobulin M(IgM)and immunoglobulin G(IgG)levels before and after treatment in the two groups of patients,the immune system was explored.The recovery of the function.Results Before treatment,there was no significant difference in serum immunoglobulin levels between the two groups(P>0.05).After treatment,serum immunoglobulin A(IgA)and immunoglobulin M(IgM)were used in the experimental group.The level of immunoglobulin G(IgG)was significantly higher than that of the control group,and the difference between the groups and the group was statistically significant(P<0.05).Conclusion Synchronous chemoradiotherapy can effectively restore the immune function of patients with advanced esophageal cancer,thus improving the clinical treatment effect.Therefore,this treatment can be applied to the treatment of patients with advanced esophageal cancer.
作者 邰璐 刘永新 TAI Lu;LIU Yong-xin(Department of Oncology,82nd Hospital of the Chinese People’s Liberation Army,Huaian,Jiangsu 223001)
出处 《智慧健康》 2019年第29期104-105,124,共3页 Smart Healthcare
关键词 同步放化疗 中晚期食管癌 免疫功能 影响 Concurrent chemoradiotherapy Advanced esophageal cancer Immune function Influence
  • 相关文献

参考文献8

二级参考文献69

  • 1杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1621
  • 2Lee JH,Kim SH,Oh SY,et al. Third-line docetaxel chemothera-py for recurrent and metastatic gastric cancer[J]. Korean J In-tern Med,2013,28(3) :314-321.
  • 3Luo H, Yu Z,Gao H,et al. Efficacy and tolerability of docetaxeland cisplatin plus S-l for advanced gastric cancer[J]. J BUON,2013,18(1):154-161.
  • 4Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit withdocetaxel plus fluorouracil and cisplatin compared with cisplatin andfluorouracil in a phase trial of advanced gastric or gastroesophagealcancer adenocarcinoma: the V-325 Study Group [J]. J Clin Oncol,2007,25C22):3205-3209.
  • 5Kanat O,O’Neil BH. Metastatic gastric cancer treatment:a lit-tle slow but worthy progress[J]. Med Oncol,2013.30(1) :464.
  • 6Huang D,Ba Y, Xiong J, et al. A multicentre randomised trialcomparing weekly paclitaxel + S-l with weekly paclitaxel +5-fluorouracil for patients with advanced gastric cancer[J]. Eur JCancer,2013,49(14):2995-3002.
  • 7Van Cutsem E,Moiseyenko VM,Tjulandin S,et al. Phase HI study ofdocetaxel and cisplatin plus fluorouracil compared with cisplatin and flu-orouracil as first-line therapy for advanced gastric cancer:a report of theV325 study group[J], J Clin Oncol,2006,24(31) :4991-4997.
  • 8Kim YS,Sym SJ * Park SH, et al. A randomized phase II studyof weekly docetaxel/cisplatin versus weekly docetaxel/oxalipla-tin as first-line therapy for patients with advanced gastric cancer[J]. Cancer Chemother Pharmacol,2014,73(1) : 163-169.
  • 9Montagnani F, Turrisi G, Marinozzi C,et al. Effectiveness andsafety of oxaliplatin compared to cisplatin for advanced, unresect-able gastric cancer: a systematic review and meta-analysis [J].Gastric Cancer,2011,14(1) :50-55.
  • 10Terazawa 丁,Iwasa S, Takashima A, et al. Impact of adding cis-platin to S-l in elderly patients with advanced gastric cancer[J].J Cancer Res Clin Oncol ,2013 ,139(12) :2111-2116.

共引文献167

同被引文献8

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部